The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory ...

Aug 5 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the ...

The Food and Drug Administration on Wednesday approved the U.S.’s first flu shot that uses mRNA technology: mFlusiva, from ...

The vaccine could give Moderna a foothold in seasonal flu and strengthen the case for mRNA shots against fast-changing ...

Moderna received FDA approval for its new mRNA-based flu shot for older adults after months of regulatory questioning.

The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on ...

The decision caps a seven-month review that included a rare refusal to consider the shot at all.

In a first, the U.S. has approved an influenza vaccine that relies on mRNA technology—the same technology that underpinned ...

The FDA has approved Moderna's mRNA-based seasonal flu vaccine for adults 50 and older, marking the first such approval in the U.S.

The FDA has approved Moderna’s influenza vaccine, the first licensed flu shot made using messenger RNA technology.

Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.